Based on existing evidence, there may be great differences in tumor biology between patients with NSCLC harboring TP53 mutations and those without TP53 mutations (Mogi and Kuwano, 2011; Jamal-Hanjani et al., 2017; Bailey et al., 2018; Birkbak and McGranahan, 2020). Here, TP53 is linked to neoplasm.